Immunoadsorption ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica2
14Chronic inflammatory demyelinating polyneuropathy1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04450030
(ClinicalTrials.gov)
August 1, 201824/6/2020Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple SclerosisImmunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis - Assessment of Mechanism of ActionMultiple Sclerosis, Relapsing-RemittingDrug: Methyl Prednisolonate;Procedure: ImmunoadsorptionUniversity Hospital MuensterNULLActive, not recruiting18 Years65 YearsAll204Germany
2EUCTR2017-000635-13-DE
(EUCTR)
08/06/201822/02/2018Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorptionEscalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption Multiple Sclerosis (MS), acute episode
MedDRA version: 20.0;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
INN or Proposed INN: Methylprednisolone
Other descriptive name: METHYLPREDNISOLONE
Universität LeipzigNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140Phase 3Germany

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 167 Drugs : 158 - (DrugBank : 38) / Drug target genes : 13 - Drug target pathways : 23
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04881682
(ClinicalTrials.gov)
January 1, 202228/4/2021Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CIDPDevice: Immunoadsorption;Biological: ImmunoglobulinsUniversity of UlmMiltenyi Biomedicine GmbHNot yet recruiting18 YearsN/AAll20Phase 2Germany